Gradientech carries out a rights issue of approximately SEK 60 million
The Board of Directors of Gradientech AB (publ) (“Gradientech” or “the Company”) decided on 17 December to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 60 million (the “Rights Issue”). A prospectus regarding the Rights Issue has today been approved by the Swedish Financial Supervisory Authority and is available on the Company's website gradientech.se.
Investor presentation on 22 Januari 2025
Shareholders are welcome to participate at Gradientech’s investor presentation that is arranged at Redeye’s premises at Mäster Samuelsgatan 42 in Stockholm on 22 January 2025 at 6-7 pm CET. The event is also possible to attend online. For registration go to Redeye’s website redeye.se.
Terms for the Rights Issue
Those registered as a shareholder on the record date of 15 January 2024, has a preferential right to subscribe for ordinary shares in the Rights Issue in relation to the number of ordinary shares held on the record date. One (1) existing share in the Company entitles to one (1) subscription right. Twentyfive (25) subscription rights entitle to subscribe for three (3) new shares.
The subscription price is SEK 17.50 per new share. If the offer is fully subscribed, the number of shares in the Company will increase from 28,867,173 shares to 32,331,233 shares, corresponding to a dilution effect of approximately 11 percent. Subscription of shares shall take place during the period from and including 17 January 2025 to and including 31 January 2025. The Board has the right to extend the subscription and payment period. Aqurat Fondkommission AB acts as an issuing agent in connection with the Rights Issue.
Subscription commitments
In connection with the Rights Issue, the Company has received subscription commitments totalling approximately SEK 51 million, corresponding to approximately 84 percent of the Rights Issue. No compensation is paid for submitted subscription commitments.
Prospectus
Complete terms and conditions for the Rights Issue as well as other information about the Company and information about subscription commitments appear in the prospectus that is available on the Company's and the Swedish Financial Supervisory Authority respective websites (gradientech.se, fi.se).
For further information, please contact:
Sara Thorslund, CEO
Tel: + 46 763 29 35 80
sara.thorslund@gradientech.se
Urban Adolfsson, CFO
Tel: + 46 708 20 72 09
urban.adolfsson@gradientech.se
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, contributes to the effective management of sepsis patients by supporting antibiotic treatment decisions in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.